Tuesday , December 10 2019
Home / zimbabwe / Non Alcoholic Fatty Liver Disease Market (NAFLD) – Pipeline Insight Report 2019 – ResearchAndMarkets.com – Press Release

Non Alcoholic Fatty Liver Disease Market (NAFLD) – Pipeline Insight Report 2019 – ResearchAndMarkets.com – Press Release



DUBLIN – (Business Wire) – O "Not
Alcoholic Fatty Liver Disease (NAFLD) – Insight Pipeline, 2019 "

pipeline drug was added to ResearchAndMarkets.com
offer.

Non-Alcoholic Fatty Liver Disease (NAFLD) – Insight Pipeline, 2019
report provides comprehensive view of the pipeline (under development)
Therapeutic scenario and growth prospects in non-alcoholic fats
Development of liver disease (NAFLD).

The report provides detailed coverage of the pipeline scenario for this
mechanism of action, equipped with data from multiple sources with
complete pipeline analysis by stage of development,
indications, route of administration and type of molecule.

Coverage of therapeutic pipeline development provides descriptive products
including but not limited to the description of the medicinal product,
development and R & D activities, covering both clinical and preclinical activities.
studies, designations, collaborations, licensing agreements, grants,
technologies and patent details.

The report assesses Active Non-Alcoholic Fatty Liver Disease (NAFLD)
pipeline products by stage of development, type of product, type of molecule,
and route of administration.

Key topics addressed:

1. Introduction Report

2. Non-alcoholic fatty liver disease (NAFLD)

3. Pipeline Therapeutics

  • An overview of pipeline products for non-alcoholic fatty liver disease
    (NAFLD)

4. Comparative Analysis

5. Clinical products

  • Product description

  • Research and Development

  • Product Development Activities

6. Pre-clinical and discovery products

  • Product description

  • Research and Development

  • Product Development Activities

7. Therapeutic Evaluation

  • Assessment by administration

  • Assessment by Internship and Administration Route

  • Evaluation by type of molecule

  • Assessment by Stage and Type of Molecule

8. Inactive Products
8.1 Name of the Medication: Name of the Company

  • Product description

  • Research and Development

  • Product Development Activities

Companies mentioned (partial list)

  • Allergan Plc

  • Arisaph Pharmaceuticals Inc

  • AstraZeneca Plc

  • Betagenon AB

  • Bird Rock Bio Inc

  • Can-Fite BioPharma Ltd

  • Cerenis Therapeutics Holding SA

  • Conatus Pharmaceuticals Inc

  • CymaBay Therapeutics Inc

  • Daewoong Pharmaceutical Co Ltd

For more information on this drug pipeline report, please visit https://www.researchandmarkets.com/research/rmb9lk/non_alcoholic?w=4

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
Toll free in USA / Canada
1-800-526-8630
To GMT Office Hours Call + 353-1-416-8900
Related
Topics: Liver
and kidney disorders drugs


Source link